Sugi Predict

Sugi Predict / Targets / GRM1

GRM1

Metabotropic glutamate receptor 1 · Q13255 · GRM1 on Sugi Atlas →

59,921 patent compounds predicted against GRM1, 30,590 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL73964 SCHEMBL73964 0.60 11/20
SCHEMBL64701 SCHEMBL64701 0.55 11/20
SCHEMBL64945 SCHEMBL64945 0.55 11/20
SCHEMBL171730 SCHEMBL171730 0.52 11/20
SCHEMBL62947 SCHEMBL62947 0.51 11/20
SCHEMBL63673 SCHEMBL63673 0.51 11/20
SCHEMBL349200 SCHEMBL349200 0.50 11/20
SCHEMBL349201 SCHEMBL349201 0.46 11/20
SCHEMBL83700 SCHEMBL83700 0.55 9/20
SCHEMBL83151 SCHEMBL83151 0.52 9/20
SCHEMBL282496 SCHEMBL282496 0.48 9/20
SCHEMBL310606 SCHEMBL310606 0.45 9/20
SCHEMBL115682 SCHEMBL115682 0.47 6/20
SCHEMBL75299 SCHEMBL75299 0.40 6/20
SCHEMBL252467 SCHEMBL252467 0.40 6/20
SCHEMBL234064 SCHEMBL234064 0.55 5/20
SCHEMBL179722 SCHEMBL179722 0.47 5/20
SCHEMBL181939 SCHEMBL181939 0.44 5/20
SCHEMBL95975 SCHEMBL95975 0.43 5/20
SCHEMBL148272 SCHEMBL148272 0.41 5/20

Clinical trials — most relevant to GRM1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Treatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine PHASE4COMPLETED
Memantine for Refractory OCD Patients PHASE3UNKNOWN
TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders PHASE3RECRUITING
A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial PHASE2/PHASE3NOT_YET_RECRUITING
Independent Studies of Dextromethorphan and of Donepezil Hydrochloride for Rett Syndrome PHASE3UNKNOWN
Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia PHASE2COMPLETED
High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia PHASE2UNKNOWN
Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder PHASE2COMPLETED
A Proof-of-Concept Trial on the Effect of Ketamine on Fatigue PHASE1/PHASE2COMPLETED
Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders PHASE2COMPLETED
TRPM8 Activators for Peripheral Neuropathy PHASE2ACTIVE_NOT_RECRUITING
PET Imaging of Brain mGluR5 Receptors Using [18F]SP203 PHASE1COMPLETED
Evaluation of Two Radioactive Chemicals to Image mGluR5 Receptors in Brain PHASE1COMPLETED
Brain Imaging, Genetics and Treatment for Major Depression PHASE1WITHDRAWN
N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia PHASE1COMPLETED
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response PHASE1RECRUITING
Riluzole in Women With Stage I, Stage II, or Stage IIIA Breast Cancer PHASE1WITHDRAWN
A Study of [11C]JNJ-42491293, a Possible PET Ligand for the mGlu2 Receptor, in Healthy Adult Volunteers PHASE1COMPLETED
D-aspartate and Therapeutic Exercise EARLY_PHASE1UNKNOWN
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine EARLY_PHASE1COMPLETED
Changes in Glutamatergic Neurotransmission of Severe TBI Patients EARLY_PHASE1SUSPENDED
PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX nanCOMPLETED
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease nanCOMPLETED
Acamprosate: Genes Associated With Response nanCOMPLETED
Tolerability and Efficacy of L-Serine in Patients With GRIN-related Encephalopathy nanUNKNOWN
Sleep/Wake Cycle and Depression: An Imaging and Treatment Study nanCOMPLETED
Metabotropic Receptors For Glutamate Type 3 In Parkinson's nanUNKNOWN
Integrins and Protocadherins in Glutamatergic Circuits: Identification of Common Signaling Pathways and Molecular Targets in Anxiety and Major Depressive Disorders (GAPsy) nanUNKNOWN
Examination of Glutamate and mGluR5 in Psychiatric Disorders nanCOMPLETED
Effect of D-cycloserine on Extinction of Fear Conditioning nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a GRM1 binder may also engage these)

ProteinNameSimilarity
GRM5 Metabotropic glutamate receptor 5 1.000 landscape →
P97772 — 1.000 P97772 →
Q3UVX5 — 1.000 Q3UVX5 →
P23385 — 1.000 P23385 →
P31424 — 1.000 P31424 →
Q5RAL3 — 1.000 Q5RAL3 →
Q1ZZH1 — 0.998 Q1ZZH1 →
GRM3 Metabotropic glutamate receptor 3 0.998 landscape →
Q9QYS2 — 0.997 Q9QYS2 →
P91685 — 0.997 P91685 →
Q09630 — 0.997 Q09630 →
G5ECB2 — 0.995 G5ECB2 →
CASR Extracellular calcium-sensing receptor 0.992 landscape →
P31422 — 0.991 P31422 →
H2L0Q3 — 0.991 H2L0Q3 →
P48442 — 0.991 P48442 →
Q9QY96 — 0.991 Q9QY96 →
O62714 — 0.991 O62714 →
Q80T41 — 0.990 Q80T41 →
P35384 — 0.989 P35384 →
O70410 — 0.989 O70410 →
B3LZ39 — 0.989 B3LZ39 →
Q9PW88 — 0.988 Q9PW88 →
B4MU83 — 0.988 B4MU83 →
B4JHV0 — 0.988 B4JHV0 →
Q38PU2 — 0.987 Q38PU2 →
B1AS29 — 0.987 B1AS29 →
Q24418 — 0.987 Q24418 →
P42264 — 0.987 P42264 →
Q60934 — 0.987 Q60934 →